Crossmark

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2

Published Online: 2021-11-12

Published Print: 2021-12

Authors

Romagnoli, Simone

Bartalucci, Niccolò

Gesullo, Francesca

Balliu, Manjola

Bonifacio, Stefania

Fernandez, Anair Graciela Lema

Mannelli, Francesco

Bolognini, Davide

Pelo, Elisabetta

Mecucci, Cristina

Guglielmelli, Paola

Vannucchi, Alessandro Maria
Funding

Funding for this research was provided by:

associazione italiana per la ricerca sul cancro (#21267)

fondazione cassa di risparmio di firenze (#46400)
License Information

Text and Data Mining valid from 2021-11-12

Version of Record valid from 2021-11-12
More Information

Article History

Received: 19 August 2021

Accepted: 20 October 2021

First Online: 12 November 2021

Declarations

:

: The study was performed in compliance with the local ethics committee approval (#14,560) obtained for the AIRC-MYNERVA Project (#21,267).

: All the listed authors read the manuscript and approved the submitted data for publication.

: AMV : member of advisory board of GSK, Incyte, Novartis, Blueprint ; speaker for Novartis, Incyte, Abbvie, BMS. PG : member of advisory board of Novartis, Abbvie. FM : member of advisory board of Novartis. CM : member of advisory board of Celgene ; member of editorial board of Dynamicon. There is no conflict of interest related to the current work to disclose for any of the other authors.

Document is current